Duncan Bucknell

Strategic Intellectual Property

Menu
  • Our Services
  • Insights & News
  • How we help you succeed
  • About us

Duncan Bucknell

Strategic Intellectual Property

Duncan

Posts by Duncan:
  • New Article – Novartis' glivec battle with India – patentability of pharmaceutical extension patents
  • New Article – Australia even more patent-friendly after High Court decision
  • Australia even more patent-friendly after High Court decision
  • Patent litigation in India – uncommon and in need of reform?
  • PubPat – the public interest patent challenger
  • Where (not) to litigate IP
  • Top Global Brands 2007
  • Participatory media & IP – great podcast
  • Lipitor (Zarator or Cardyl) in Spain – mixed success but no launch for Ranbaxy
  • What to do in the US if you don't have standing to sue for revocation – more on Benitec v Nucleonics
« 1 … 143 144 145 146 147 … 152 »
Duncan Bucknell
duncan@duncanbucknell.com
+61 427 003 423

Insights & News

  • Commercial IP, deals and contracts
  • Disputes and Litigation
  • IP Rights
    • Brands and Trade Marks
    • Copyright and Designs
    • Inventions & Patents
    • Trade Secrets
  • Strategic Advice
    • Coaching
    • Develop IP
    • Enforce and defend your IP
    • Increase IP Value
    • Inform and improve your IP Strategy
    • IP Management
    • Product Strategy
    • Pursue Excellence
    • Risk management

Liability limited by a scheme approved under Professional Standards Legislation

Duncan Bucknell

Loading Comments...

You must be logged in to post a comment.